Sodium-glucose co-transporter-2 inhibitors: A paradigm shift in treatment for type 2 diabetes

Diabetes Obes Metab. 2024 Oct:26 Suppl 5:3-4. doi: 10.1111/dom.15963.
No abstract available

Keywords: SGLT2 inhibitor; canagliflozin; cardiovascular disease; heart failure.

Publication types

  • Editorial

MeSH terms

  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Hypoglycemic Agents* / therapeutic use
  • Sodium-Glucose Transporter 2 / metabolism
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • Sodium-Glucose Transporter 2 Inhibitors
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2
  • Blood Glucose